PM360
AUGUST 9, 2022
According to a 2021 study by Statista, 40% of prescriptions written in 2005 were for brand-name medications. 2 and over a million actively licensed physicians 3 are available to prescribe them? By 2020, that percentage plummeted to just 8%. References: 1. Symphony Health Solutions, practitioner insight’s data, 2022.
European Pharmaceutical Review
APRIL 21, 2023
2 A study found that pharmaceuticals and other chemical products are responsible for 40 percent of the Dutch healthcare system’s greenhouse gas emissions and about 80 percent of its share of material extraction. The environmental impact of the Dutch healthcare sector beyond climate change: an input-output analysis. 2022; 6: 949-57.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 5, 2022
In 2009, former Biogen employee Michael Bawduniak filed a lawsuit claiming that Biogen had violated the False Claims Act and the Anti-Kickback Statute by providing millions of dollars to healthcare providers (HCPs) as an incentive to prescribe three of its multiple sclerosis (MS) drugs. Biogen’s activity in multiple sclerosis.
European Pharmaceutical Review
JULY 13, 2023
In many European countries physicians can now prescribe medical cannabis for an array of chronic health conditions, including chronic pain, mental health disorders and neurological conditions. 2005 Dec;146(7):913-5. 1,2 Yet the pace of adoption in Europe has notably lagged countries such as Canada, Australia and the US. Mechoulam R.
European Pharmaceutical Review
DECEMBER 19, 2023
Over his career as a physician and scientist he published 108 papers and 49 patents. It has potential to be applied simply and directly to most existing commercial vaccines. Since vaccines can now be reformulated to meet the relevant WHO guidelines, the route to a future of fridge-free vaccines is open. Maillard Reaction and Drug Stability.
Evolve Your Success
JUNE 28, 2022
I visited the Philippines in 2005. In Philadelphia, it was my first North American Spine Society in 2005. We give them this very quantitative assessment of their idea based on market size, the clinical need, and the attractiveness as a physician call point. That’s the fun part about healthcare innovation. Click To Tweet.
Pharmaceutical Technology
OCTOBER 5, 2008
According to market intelligence provider Pharmaceutical Insights, Japan’s $6m generic drug sector is currently experiencing a renaissance, primarily because the government wants to control healthcare costs. “Physicians still feel concerned about generic drug use, but now they have more power,” says Sato.
Expert insights. Personalized for you.
52 
Let's personalize your content